Abraham Dada

Abraham Dada

Auto-generated profile, based on publicly available information

Abraham Dada

Department of Neurosurgery, University of California, San Francisco, San Francisco, CA 94143, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
JBJoshua Bernstock
Joshua Bernstock
MMMulki Mehari
Mulki Mehari
JGJakob V. E. Gerstl
Jakob V. E. Gerstl
DMDavid M. Meredith
David M. Meredith
PVPablo A. Valdes
Pablo A. Valdes
SHShawn Hervey-Jumper
Shawn Hervey-Jumper
Neuronal-glioma interactions are increasingly recognized as critical in the development and progression of central nervous system tumors. Recent research highlights that gliomas can integrate into neural circuits through various mechanisms, including the synaptogenic factor thrombospondin-1 (TSP-1). This new mechanistic understanding of cancer neuroscience allows for novel insights into target discovery. Critically, therapies that modulate neuron-tumor interactions remain agnostic to other oncogenic changes within tumor cells yet may still target fundamental drivers of tumor growth. In line with these findings and controlling for critical confounding variables, we demonstrate a survival benefit associated with gabapentin (an antagonist of TSP-1) following surgical resection of newly diagnosed glioblastoma. This retrospective, multi-institutional cohort study included 1,072 patients, with a discovery cohort of 693 patients and an additional 379 patients from a separate site for external validation. Furthermore, our findings indicate that gabapentin administration is associated with reduced serum TSP-1 levels, suggesting its potential as a future biomarker.

6 June 2025 in Science Advances
Verified
Journal Article
Open access
MMMulki Mehari
Mulki Mehari
GWGayathri Warrier
Gayathri Warrier
ADAbraham Dada
Abraham Dada
AKAymen Kabir
Aymen Kabir
AHAden P. Haskell-Mendoza
Aden P. Haskell-Mendoza
SHShawn Hervey-Jumper
Shawn Hervey-Jumper
Therapeutic clinical trial enrollment does not match glioma incidence across demographics. Traditional statistical methods have identified independent predictors of trial enrollment; however, our understanding of the interactions between these factors remains limited. To test the interactive effects of demographic, socioeconomic, and oncologic variables on trial enrollment, we designed boosted neural networks (BNNs) for all glioma patients ( n = 1042), women ( n = 445, 42.7%), and minorities ( n = 151, 14.5%) and externally validated these models [whole cohort, n = 230; women, n = 89 (38.7%); minority, n = 66 (28.7%)]. For the whole-cohort BNN, the most influential variables on enrollment were oncologic variables, including KPS [total effect (TE), 0.327], chemotherapy (TE, 0.326), tumor location (TE, 0.322), and seizures (TE, 0.239). The women-only BNN exhibited a similar trend. Conversely, for the minority-only BNN, socioeconomic variables [insurance status (TE, 0.213), occupation classification (TE, 0.204), and employment status (TE, 0.150)] were most influential. These results may help prioritize patient-specific initiatives to increase accrual.

25 September 2026 in Science Advances
Verified
Journal Article
Open access
SHSanjeev Herr
Sanjeev Herr
NONiels Olshausen
Niels Olshausen
MPMelike Pekmezci
Melike Pekmezci
JKJasleen Kaur
Jasleen Kaur
YSYoussef Sibih
Youssef Sibih
SHShawn Hervey-Jumper
Shawn Hervey-Jumper
A hallmark of glioblastoma (GBM) is disease recurrence that occurs in all patients despite resection, radiation, and chemotherapy. A critical challenge in GBM treatment is the management of recurrent disease for which no standard of care exists. Predicting the location of GBM recurrence may improve the efficiency of advanced-stage therapies. We present an artificial intelligence (AI)–based model to predict the recurrence risk of unprocessed surgical tissues at initial resection. AI-informed label-free optical microscopy was used to generate a normalized tumor infiltration value (AI-infiltration) for optical images of samples taken from resection cavity margins. These values, in combination with clinical, radiographic, and molecular variables, were used to build a predictive model of focal recurrence. In a cohort of 80 patients, comprising 367 samples and 133,454 unique images, GBM infiltration was significantly higher in margin samples from recurrent sites ( P = 0.03) compared with those from nonrecurrent sites. A random forest machine learning classifier predicted site recurrence with an average area under the receiver operating characteristic curve of 87% ± 10.0 for the training cohort and 80% (95% confidence interval: 0.64 to 0.97) for the validation cohort. AI-infiltration was the strongest contributor to recurrence prediction, outperforming tumor molecular features. Model performance remained high regardless of tumor location, resulting in random forest model predictions of recurrence at 5 and 10 millimeters of each sample. These findings represent the potential of AI to predict sites of tumor recurrence, thereby improving accessibility to targeted, precision, and multimodal therapy for the highest-risk areas of disease.

17 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
AKAymen Salahadin Kabir
Aymen Salahadin Kabir
ADAbraham Dada
Abraham Dada
WSWesley Shoap
Wesley Shoap
RRRithvik Ramesh
Rithvik Ramesh
DQDaniel Quintana
Daniel Quintana
EGEzequiel Goldschmidt
Ezequiel Goldschmidt
Background: Meningioma–induced hyperostosis (MIH) is a frequent radiographic finding, yet its underlying mechanisms remain poorly understoodWhile hyperostosis has traditionally been treated as a binary phenomenon, the aim of this study was to determine whether MIH represents a heterogenous process with distinct radiological subtypes associated with genetic associations. Methods: We retrospectively reviewed the records and imaging of patients with meningiomas resected between 2021–2024 at a single institution. Somatic mutations identified through next–generation sequencing were analyzed. CT images were analyzed for bone involvement and hyperostosis subtype. Type I hyperostosis was defined by destruction of cortical architecture while Type II hyperostosis was defined by the preservation of cortical structure. Associations with TRAF7 mutations were assessed using univariate testing, multivariable logistic regression, and supervised machine–learning models. Quantitative bone density analysis was performed using region–of–interest grayscale histogram analysis. Results: Among 384 tumors, 54 (14.1%) exhibited hyperostosis—23 Type I and 31 Type II. TRAF7 mutations were significantly enriched in Type I hyperostosis compared with Type II and non–hyperostotic tumors (78.3% vs 25.8% vs 17.0%, p<0.001). Type I hyperostosis independently predicted TRAF7 mutations (OR:18.73, p=0.001), along with skull base location, smaller tumor size, homogeneous contrast enhancement, and extensive T2 hyperintensity. Gradient boosting achieved the highest predictive accuracy (AUC=0.854). Quantitative bone density analysis demonstrated preserved cortical–cancellous architecture in Type II hyperostosis, whereas Type I showed architectural disruption. Conclusions: MIH is a radiographically heterogenous phenomenon. Hyperostosis with disrupted cortical architecture is strongly associated with TRAF7 mutations and may represent a key feature of this mutation's radiographic phenotype.